The results of this experiment have confirmed that KM110r is an effective and safe oncolytic virus therapy because of its ability to successfully terminate cancer cells and to ignore non-cancerous cells. This result substantiates KM110r as an effective cancer therapy and worthy of being developed into an oncolytic virus.

In the 34°C temperature trial all U2OS cells were 100% dead by time period 4, and in the 37°C temperature trial all U2OS cells were 100% dead by time period 3 in the first trial, and by time period 2 in the second. However in the 39°C trials by time period 4, an average of 26% lysis of U2OS cells occurred. These findings demonstrate that 34°C conditions delay cell death, and 39°C conditions either do not permit complete cell death or may simply delay cell death. Therefore, it appears that KM110r optimally kills cancerous cells at 37°C. However this makes sense, given that HSV-1 (from which KM110r was developed) is a virus that has evolved in a human host environment. Therefore the virus has adapted to human conditions, one if which is the human physiological (body) temperature of 37°C, thus making it its optimal temperature condition.

This investigation did not support identification of a point during in vitro cell differentiation at which hFOB cells become permissive to KM110r. Consequently, it is still unclear why the virus is safe in normal cells. However, this reveals a very advantageous quality of the virus from a gene therapeutics perspective. The differentiation that occurred in the hFOB cells at 39°C are changes that would generally occur in a normal precursor bone cells. Thus it is clear that the virus is able to distinguish between normal cell differentiation and cancer, and is able to ignore normal cell differentiation.

At each temperature trial, hFOB cells grew at equal rates regardless of their viral infection status. Standard error and t-probability statistical analyses showed that the difference between hFOB infected and hFOB uninfected growth rates was not statistically significant. This continues to verify the resistance of normal cells to KM110r.

The U2OS infected growth trends were determined to be significantly different at each temperature range, as confirmed by standard error and ANOVA tests. These results demonstrate the distinct variations in U2OS growth at different temperature conditions. This implies that irregular changes are occurring in the U2OS cells as a result of temperature changes, which may alter the efficacy of the virus.

Although further experimentation and interpretation is required in extrapolating the data from an in vitro to an in vivo setting (i.e. humans), the present findings of this experiment are highly indicative of the efficacy of KM110r to terminate cancer cells and to ignore non-cancerous cells.